(Q40622636)

22 September 2017

title

Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia (English)

1 reference

22 September 2017

0 references

1 reference

1 reference

2

Lusher JM

1 reference

22 September 2017

Ragni MV

1

1 reference

22 September 2017

Koerper MA

series ordinal

3

1 reference

22 September 2017

Manco-Johnson M

series ordinal

4

1 reference

22 September 2017

Krause DS

series ordinal

5

1 reference

22 September 2017

publication date

1 March 2000

1 reference

22 September 2017

1 reference

22 September 2017

volume

6

1 reference

22 September 2017

issue

2

1 reference

22 September 2017

page(s)

98-103

1 reference

Will hepatitis A become a vaccine-preventable disease?

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

Detection of hepatitis A virus RNA in commercially available factor VIII preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

Prevalence of serum IgG antibodies to hepatitis A virus in Italian haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

Passive antibody to hepatitis A virus in US haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

Vaccination against hepatitis A virus in French hemophilic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

Long-term immunogenicity and safety of an inactivated hepatitis A vaccine in haemophilic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

A study to assess the immunogenicity, reactogenicity and safety of hepatitis A vaccine administered subcutaneously to patients with congenital coagulation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

Time course of hepatitis A antibody production after active, passive and active/passive immunisation: the results are highly dependent on the antibody test system used

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

Association of changes in monocyte antigen presentation and cytokine production in haemophilic boys with treatment and blood‐borne virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

Protection against hepatitis A by an inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2000.00386.X

10.1046/J.1365-2516.2000.00386.X

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference